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Background: Idiopathic dilated cardiomyopathy (DCM), the most common form of cardiomyopathy, affects approximately 1:2500 people. Up to 
1/3 of individuals with idiopathic DCM have familial dilated cardiomyopathy due to heritable gene mutations. Of the more than 25 genes so far 
identified in association with DCM, the clinical features and genetic mechanisms can be diverse. Familial DCM is often caused by mutations in genes 
encoding sarcomeric proteins, however, clinical genetic testing is increasingly incorporating non-sarcomeric genes in multi-gene test panels. This is 
helping to further define the genetic etiology of familial DCM.
Methods: 248 consecutive patient samples were included, each with the indication for genetic testing based on a diagnosis by the referring 
physician of DCM. Utilizing an Illumina NextGeneration sequencing platform in a CLIA-certified laboratory, the entire coding region and the intron/
exon splice regions of 27 genes associated with familial DCM were sequenced (LMNA, MYH7, TNNT2, ACTC1, DES, MYBPC3, TPM1, TNNI3, ZASP, TAZ, 
PLN, TTR, LAMP2, SGCD, MTTL1,MTTL2, MTTD, MTTI, MTTQ, MTTH, MTTK, MTTM, MTTS1, MTTS2, MTND1, MTND5, MTND6).
Results: In the 248 unrelated patients tested, 73 were found to have at least one mutation (positive rate = 29%), of whom 10 (4%) had two 
mutations in the same gene or two different genes. Of the 8 two-mutation cases with available clinical information, 5 were diagnosed before one 
year of age. Mutations in MYH7 and MYBPC3 accounted for 23 (28%) and 15 (18%) of identified mutations, respectively. Mutations in genes coding 
for non-sarcomeric proteins accounted for 33% of the mutations identified.
Conclusion: In this cohort of individuals with suspected familial DCM, a significant proportion harbor a mutation in a non-sarcomeric gene. The 
heterogeneous nature of DCM was also evident in the 4% of individuals with multiple mutations. The complete clinical and genetic spectrum of 
familial DCM remains to be elucidated. However, it is apparent that the diagnosis of familial DCM will continue to require evaluation of an increasing 
number of genes, given the genetic complexity and lack of a singular genetic cause of this condition.
